Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

Autor: Mark Fineman, L A Kinninger, T Darsow, Kenneth F. Mace, Brenda Cirincione, Michael E. Trautmann, Michaela Diamant, T. K. Booker Porter

Publikováno v: Fineman, M S, Mace, K F, Diamant, M, Darsow, T, Cirincione, B B, Porter, T K B, Kinninger, L A & Trautmann, M E 2012, ' Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment ', Diabetes, Obesity and Metabolism, vol. 14, no. 6, pp. 546-554 . https://doi.org/10.1111/j.1463-1326.2012.01561.x
Diabetes, Obesity and Metabolism, 14(6), 546-554. Wiley-Blackwell

Aims: Antibody formation to therapeutic peptides is common. This analysis characterizes the time-course and cross-reactivity of anti-exenatide antibodies and potential effects on efficacy and safety. Methods: Data from intent-to-treat patients in 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87fd81b183201c9dbda5a6ddd3fc1832
https://research.vumc.nl/en/publications/6d92f799-1cd2-4000-8038-f937b612fb9a

Pramlintide in the treatment of diabetes

Autor: S V, Edelman, T, Darsow, J P, Frias

Publikováno v: International journal of clinical practice. 60(12)

Diabetes treatment has traditionally focused on correcting insulin deficiency with exogenous insulin and oral agents designed to enhance insulin secretion or insulin sensitivity in peripheral tissues. The more recent view of diabetes as a disease tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9d2d98307fc5a1a50e296f8c3d8cb0fd
https://pubmed.ncbi.nlm.nih.gov/17109659

PO43 - Les anticorps anti-exénatide ne réagissent ni avec le GLP-1 humain, ni avec le glucagon et n’altèrent ni l’efficacité, ni la sécurité d’un traitement par exénatide

Autor: Brenda Cirincione, B. Porter, Kenneth F. Mace, Michael E. Trautmann, C. Salaun-Martin, Mark Fineman, Michaela Diamant, T. Darsow

Publikováno v: Diabetes & Metabolism. 37:A34

Introduction Les peptides pharmaceutiques etant immunogeniques, les patients traites par exenatide peuvent developper des anticorps anti-exenatide (ACexe). La presente analyse decrit l’evolution au cours d’un traitement par exenatide des taux d�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5629040314f08a8fca8231f6aaa67a1
https://doi.org/10.1016/s1262-3636(11)70621-8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.